What is the 13F Pro Quality Score for LNAI?

13F Pro ranks Lunai Bioworks Inc. (LNAI) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View LNAI's current score at https://13fpro.ai/research/LNAI (free sign-up required for the full ranking).

Which hedge funds own the most LNAI stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of LNAI include GEODE CAPITAL MANAGEMENT,, BlackRock,, NINE MASTS CAPITAL Ltd. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/LNAI as soon as new 13F filings post.

Where does 13F Pro source LNAI data?

All Lunai Bioworks Inc. fundamentals and ownership data come directly from SEC EDGAR. Lunai Bioworks Inc. files with the SEC under CIK 1527728. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is LNAI in?

Lunai Bioworks Inc. (LNAI) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is LNAI research updated on 13F Pro?

LNAI's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Lunai Bioworks Inc.(LNAI)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1527728 LNAI stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

LNAI Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Lunai Bioworks Inc. (LNAI), a Healthcare sector company. LNAI is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q3 2026), Lunai Bioworks Inc. reports quarterly revenue of $20.9K, net income of $-2.6M, free cash flow of $-1.0M. Top institutional holders of LNAI by reported 13-F value include GEODE CAPITAL MANAGEMENT,, BlackRock,, NINE MASTS CAPITAL Ltd, based on the most recent SEC filings. LNAI trades on the Nasdaq exchange and files with the SEC under CIK 1527728. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LNAI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Lunai Bioworks Inc. directly from SEC EDGAR.

Revenue

Q3 2026

$20.9K

Net Income

Q3 2026

$-2.6M

Free Cash Flow

Q3 2026

$-1.0M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

-56.9% YoY

$-178.0MFY 2025

FY20 $-11.4MFY21 $-26.7MFY22 $-113.4MFY25 $-178.0M

Operating Income

-62.8% YoY

$-189.0MFY 2025

FY20 $-11.9MFY21 $-23.4MFY22 $-116.1MFY25 $-189.0M

EPS (Diluted)

+50.0% YoY

$-1.08FY 2025

FY20 —FY21 —FY22 $-2.16FY25 $-1.08

Total Assets

-90.3% YoY

$8.2MFY 2025

FY20 $178.1MFY21 $189.6MFY22 $84.6MFY25 $8.2M

Op. Cash Flow

+49.9% YoY

$-7.9MFY 2025

FY20 $-10.5MFY21 $-20.6MFY22 $-15.7MFY25 $-7.9M

Metric	FY 2025	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Net Income	$-178.0M -56.9%	$-113.4M -324.5%	$-26.7M -134.1%	$-11.4M +36.6%	$-18.0M -185.4%	$-6.3M
Operating Income	$-189.0M -62.8%	$-116.1M -396.0%	$-23.4M -96.3%	$-11.9M -8.5%	$-11.0M -106.2%	$-5.3M
EPS (Diluted)	$-1.08 +50.0%	$-2.16	—	—	—	—
Total Assets	$8.2M -90.3%	$84.6M -55.4%	$189.6M +6.5%	$178.1M -1.0%	$179.9M +0.1%	$179.7M
Operating Cash Flow	$-7.9M +49.9%	$-15.7M +23.7%	$-20.6M -97.1%	$-10.5M -22.9%	$-8.5M -96.1%	$-4.3M

AI Insight: LNAI Financial Trends

Lunai burned through equity to near-insolvency in Q2 2025, then stabilized losses but remains deeply underwater with negative shareholder value.

• Operating losses narrowed from $127M in Q2 2025 to $1M–$3M in Q3 2025–Q1 2026, showing cost discipline.

• Equity swung from $132M (Q2 2024) to negative $10M (Q1 2026), signaling accumulated losses exceeded paid-in capital.

• Operating cash burn stabilized at $1M–$2M quarterly since Q3 2025, down from $2M–$3M in prior periods.

⚠ Company now technically insolvent on book value; any further losses or debt covenant breach risks dilution or restructuring.

⚠ Q3 2025 net income flipped positive to $3M but remains volatile; sustainability unclear without revenue visibility.

AI Insight: LNAI Ratio Trends

Lunai Bioworks shows early signs of profitability inflection after severe losses; Q1 2025 marks first positive ROE (0.9%) in dataset, though ROIC remains negative.

• ROE recovered to 0.9% in Q1 2025 from -35.4% in Q4 2024, first positive return on equity in available history.

• ROA improved to 0.6% in Q1 2025 versus -26.1% in Q4 2024, signaling better operational efficiency relative to assets.

• ROIC narrowed loss to -18.8% in Q1 2025 from -22.2% in Q4 2024, but remains deeply negative despite directional improvement.

⚠ Data gap from Q2 2025 onward; no profitability metrics available for last nine months. Monitor for Q2+ results.

⚠ ROIC has not returned to positive territory; company still destroying capital on invested base despite near-term recovery in ROE/ROA.

Get alerted when LNAI's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Lunai Bioworks Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of LNAI

GEODE CAPITAL MANAGEMENT, LLC
$74.3K182,237 sh
BlackRock, Inc.
$51.9K127,314 sh
NINE MASTS CAPITAL Ltd
$41.7K102,426 sh
CITIGROUP INC
$40.8K100,095 sh
XTX Topco Ltd
$21.4K52,484 sh
NORTHERN TRUST CORP
$15.2K37,402 sh
STATE STREET CORP
$14.6K35,728 sh
TWO SIGMA SECURITIES, LLC
$10.2K25,095 sh
Jump Financial, LLC
$7.9K19,460 sh
Scientech Research LLC
$5.6K13,667 sh

Fund	Value	Shares
GEODE CAPITAL MANAGEMENT, LLC	$74.3K	182,237
BlackRock, Inc.	$51.9K	127,314
NINE MASTS CAPITAL Ltd	$41.7K	102,426
CITIGROUP INC	$40.8K	100,095
XTX Topco Ltd	$21.4K	52,484
NORTHERN TRUST CORP	$15.2K	37,402
STATE STREET CORP	$14.6K	35,728
TWO SIGMA SECURITIES, LLC	$10.2K	25,095
Jump Financial, LLC	$7.9K	19,460
Scientech Research LLC	$5.6K	13,667

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put LNAI on your watchlist

Track score changes the day Lunai Bioworks Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is LNAI a good stock to buy?

13F Pro's AI-powered analysis of Lunai Bioworks Inc. (LNAI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LNAI are available on the LNAI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own LNAI?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LNAI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Lunai Bioworks Inc.'s investment landscape.